

## SEQUENCE LISTING

<110> INNATE PHARMA S.A.S.  
UNIVERSITA DI GENOVA

<120> "Novel triggering receptor involved in natural cytotoxicity mediated by human Natural Killer cells and antibodies that identify the same"

<130> SEO-FR-1060

&lt;140&gt;

<141>

&lt;160&gt; 13

&lt;170&gt; PatentIn Ver. 2.1

<210> 1

<211> 674

<212> DNA

<213> Human NK cell

&lt;400&gt; 1

gcatctctctc	ccacccagaac	ctcaactgtctc	agatccattctt	cgccacaactgg	gacatctcttc	60
gacatggcctc	ggatgtgtgtt	ctgcattctgtc	atccatgggtcc	atccaggaactc	ctgtgtctctc	120
tggtgttccg	agccctctctc	gattctgtaac	cttggaaagtat	cctctcgtctt	ctctccgtccg	180
ctgtcttaac	ccacgcacga	gagactggctgc	atctgtgcgc	tcacgtgtgtt	ccgagatgag	240
gtgtgttccag	ggaggaagtgt	gaggaaatgga	accccaagctg	tcagaggcgc	ctgtccccc	300
ctctgtctctt	ccctgttctc	ctactgaccac	gacgctgagc	tgcaactgcg	ggactgtgca	360
ggccatgagc	ccacgcactcta	ctgtgtcaga	gttggaggtgc	ttggcctctt	tgctcggaca	420
gggaatggcg	ctctgctgtct	gtgtggaaaga	gaacactctc	agctaggggc	ttgtacgaac	480
ctctctcttc	gggctggatt	ctatgtgctc	agctttctct	ctgtgtccgt	ggggacacac	540
ctgtattaac	ggggccaatg	ccaactgcac	atgtggaaacc	actcgaatgt	cccatggtgc	600
ccccagaggr	tgattccaga	gcccaatgat	ccttagtctc	ctctaaaga	ccccataaa	660
ctctcccac	cact					674

<210> 2

<211> 190

<212> PRT

<213> Human NK cell

<400> 2

Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser  
1 5 10 15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly  
20 25 30

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu  
35 40 45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys  
50 55 60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu  
65 70 75 80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg  
85 90 95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val  
100 105 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu  
115 120 125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala  
130 135 140

Gly Phe Thr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val  
145 150 155 160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser  
165 170 175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro  
180 185 190

<210> 3

<211> 18

<212> PRT

<213> Human NK cell

<400> 3

Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser  
1 5 10 15

Cys Ala

<210> 4

<211> 120

<212> PRT

<213> Human NK cell

<400> 4

Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser  
1 5 10 15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile  
20 25 30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val  
35 40 45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser  
50 55 60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val  
65 70 75 80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly  
85 90 95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu  
100 105 110

His Pro Gln Leu Gly Ala Gly Thr  
115 120

<210> 5

<211> 19

<212> PRT

<213> Human NK cell

<400> 5

Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val  
1 5 10 15

Ala Val Gly

<210> 6  
<211> 33  
<212> PRT  
<213> Human NK cell

<400> 6  
Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His  
1 5 10 15  
Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys  
20 25 30

Pro

<210> 7  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:peptide derived  
from natural sequence, useful for antiserum  
production

<400> 7  
Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys  
1 5 10 15

<210> 8  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: up primer for  
NKp30 cDNA probe of for NKp30 cDNA amplification

<400> 8  
caggggcatct cgagtttccg acatggcctg gatgctgttg 40

<210> 9  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:down primer for  
NKp30 cDNA probe amplification

<400> 9  
gactaggatc cgcatgtgta ccagccccta gctgaggatg 40

<210> 10  
<211> 421  
<212> DNA  
<213> Human NK cell

<400> 10  
ttccgacatg gcctggatgc tgttgctcat ctgatcatg gtccatccag gatcctgtgc 60  
ttctctgggtg tccagcccc ctgagattcg taccctggaa ggaacctctg ccttctgtcc 120  
ctgctccttc aatgccagcc aaggagagact ggccattggc tccgtcacgt gtttccgaga 180

20250111-1111111111

```

tgaggtggtt ccagggaagg aggtgaggaa tggaaaccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccggt tcttccatga ccaccaggct gagctgcaca tcogggagct 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tgggtgtgga gaaagaacat cctcagctag gggctgttac 420
a

```

```

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence:down primer for
NKp30 cDNA amplification

```

```

<400> 11
gattttattgg ggtcttttga ag
22

```

```

<210> 12
<211> 606
<212> DNA
<213> Human NK cell

```

```

<400> 12
ttccgacatg gctcggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60
tctctgggtg tcccagcccc ctgagattcg tacccctggaa ggatcctctg ccttctctgc 120
ctgtctcttc aatgccagcc aaggagagact ggccattggc tccgtcacgt ggttccgaga 180
tgaggtggtt ccagggaagg aggtgaggaa tggaaaccca gagttcaggg gccgcctggc 240
cccacttgct tcttcccggt tcttccatga ccaccaggct gagctgcaca tcogggagct 300
gcgaggccat gacgccagca tctacgtgtg cagagtggag gtgctgggcc ttggtgtcgg 360
gacagggaat gggactcggc tgggtgtgga gaaagaacat cctcagctag gggtgtgtac 420
agtctctctc ctctgggctg gattctatgc tctcagcttt ctctctgtgg ccgtggggag 480
caccgtctat taccagggca aatgccactg tcacatggga acacactgac actcctcaga 540
tgggccccga gggtgtgatt cagagcccaag atgtccctag tctcttccaa aagaccccaa 600
taaatc
606

```

```

<210> 13
<211> 573
<212> DNA
<213> Human NK cell

```

```

<400> 13
atggcctgga tgcgttgtct catcttgatc atggctccatc caggatcctg tgcctctctg 60
gtgtccacgc cccctgagat tctaccctgt gaaggatcct ctgccttctt gccctgtccc 120
ttcaatgccg gccaaaggag actggccatt ggctccgtca ctgggttccg agatgaggtg 180
gttccaggga aggaggtgag gaatggaacc ccagagtcca ggggcccgct ggccccactt 240
gcttctctcc gtttctcca tgaccaccag gctgagctgc acatccggga cgtgcaggcg 300
catgacgccg gcattctact gtgcagagtg gaggtgtctg gccttggtgt cgggacaggg 360
aatgggactc ggctgttgtt ggagaaagaa catcctcagc taggggctgg tacatctctc 420
ctctctcggg ctggattcta tgcctgcagc tttctctctg tggccgtggg cagcacctgc 480
tattaccagg gcaaatgccg ctgtcacatg ggaacacact gccactcctc agatggggcc 540
cgaggrgtga ttccagagcc cagatgtccc tag
573

```

SEQUENCE LISTING



<110> INNATE PHARMA S.A.S.  
UNIVERSITA DI GENOVA

<120> "Novel triggering receptor involved in natural  
cytotoxicity mediated by human Natural Killer cells and  
antibodies that identify the same"

<130> SEQ-FR-1060

<140>

<141>

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 674

<212> DNA

<213> Human NK cell

<400> 1

```
ccttctcctc ccacccagac ctcactgctc agatcccctt cgccaactgg gacatcttcc 60
gacatggcct ggaatgctgt gctcatcttg atcatggctc atccaggatc ctgtgctctc 120
tgggtgtccc agccccctga gattcgtacc ctggaaggat cctctgcctt cctgcccctgc 180
tccttcaatg ccagccaaag gagactggcc attggctccg tcacgtggtt ccgagatgag 240
gtgggtccag ggaaggaggt gaggaatgga accccagagt tcagggggccg cctggcccca 300
cttgcttctt cccgttttct ccatgaccac caggctgagc tgcacatccg ggacgtgcga 360
ggccatgacg ccagcatcta cgtgtgcaga gtggaggtgc tgggccttgg tgtcgggaca 420
gggaatggga ctgggctggg ggtggagaaa gaacatcctc agctaggggc tggtagatgc 480
ctcctccttc gggctggatt ctatgctgtc agctttctct ctgtggccgt gggcagcacc 540
gtctattacc agggcaaatg ccactgtcac atgggaacac actgccactc ctcatgatgg 600
ccccgaggrr tgattccaga gccagatgt cctagtctct ctccaaaaga ccccaataaa 660
tctgcccac cact
```

<210> 2

<211> 190

<212> PRT

<213> Human NK cell

<400> 2

```
Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser
  1             5             10            15
```

```
Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly
  20             25            30
```

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu  
35 40 45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys  
50 55 60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu  
65 70 75 80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg  
85 90 95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val  
100 105 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu  
115 120 125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Arg Ala  
130 135 140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val  
145 150 155 160

Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His Cys His Ser  
165 170 175

Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys Pro  
180 185 190

<210> 3

<211> 18

<212> PRT

<213> Human NK cell

<400> 3

Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser  
1 5 10 15

Cys Ala

<210> 4

<211> 120

<212> PRT

<213> Human NK cell

<400> 4

Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Ser  
1 5 10 15

Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile  
20 25 30

Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val  
35 40 45

Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser  
50 55 60

Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val  
65 70 75 80

Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly  
85 90 95

Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu  
100 105 110

His Pro Gln Leu Gly Ala Gly Thr  
115 120

<210> 5

<211> 19

<212> PRT

<213> Human NK cell

<400> 5

Val Leu Leu Leu Arg Ala Gly Phe Tyr Ala Val Ser Phe Leu Ser Val  
1 5 10 15

Ala Val Gly

<210> 6

<211> 33

<212> PRT

<213> Human NK cell

<400> 6

Ser Thr Val Tyr Tyr Gln Gly Lys Cys His Cys His Met Gly Thr His

1

5

10

15

Cys His Ser Ser Asp Gly Pro Arg Gly Val Ile Pro Glu Pro Arg Cys  
 20 25 30

Pro

&lt;210&gt; 7

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:peptide derived  
 from natural sequence, useful for antiserum  
 production

&lt;400&gt; 7

Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly Ser Cys  
 1 5 10 15

&lt;210&gt; 8

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: up primer for  
 NKp30 cDNA probe of for NKp30 cDNA amplification

&lt;400&gt; 8

cagggcatct cgagtttccg acatggcctg gatgctgttg 40

&lt;210&gt; 9

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:down primer for  
 NKp30 cDNA probe amplification

&lt;400&gt; 9

gactaggatc cgcattgtgta ccagccccta gctgaggatg 40



<210> 10  
 <211> 421  
 <212> DNA  
 <213> Human NK cell

<400> 10  
 ttccgacatg gcttggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60  
 tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttccctgcc 120  
 ctgctccttc aatgccagcc aaggaggact ggccattggc tccgtcacgt ggttccgaga 180  
 tgaggtggtt ccagggaagg aggtgaggaa tggaaaccca gagttcaggg gccgcctggc 240  
 cccacttgct tcttcccggt tcttccatga ccaccaggct gagctgcaca tccgggacgt 300  
 gcgagggcat gacgccagca tctacgtgtg cagagtggag gtgctggggc ttggtgtcgg 360  
 gacagggaaat gggactcggc tgggtgggtga gaaagaacat cctcagctag gggctggtag 420  
 a 421

<210> 11  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:down primer for  
 NKp30 cDNA amplification

<400> 11  
 gatttatgtg ggtcttttga ag 22

<210> 12  
 <211> 606  
 <212> DNA  
 <213> Human NK cell

<400> 12  
 ttccgacatg gcttggatgc tgttgctcat cttgatcatg gtccatccag gatcctgtgc 60  
 tctctgggtg tcccagcccc ctgagattcg taccctggaa ggatcctctg ccttccctgcc 120  
 ctgctccttc aatgccagcc aaggaggact ggccattggc tccgtcacgt ggttccgaga 180  
 tgaggtggtt ccagggaagg aggtgaggaa tggaaaccca gagttcaggg gccgcctggc 240  
 cccacttgct tcttcccggt tcttccatga ccaccaggct gagctgcaca tccgggacgt 300  
 gcgagggcat gacgccagca tctacgtgtg cagagtggag gtgctggggc ttggtgtcgg 360  
 gacagggaaat gggactcggc tgggtgggtga gaaagaacat cctcagctag gggctggtag 420  
 agtcctctct cttcgggctg gattctatgc tgtcagcttt ctctctgtgg ccgtgggcag 480  
 caccgtctat taccagggca aatgccactg tcacatggga acacactgcc actcctcaga 540  
 tgggcccga ggrgtgattc cagagccagc atgtccctag tctctttcaa aagaccccaa 600  
 taaatc 606

<210> 13  
 <211> 573  
 <212> DNA

<213> Human NK cell

<400> 13

```
atggcctgga tgctgttgct catcttgatc atgggtccatc caggatcctg tgctctctgg 60
gtgtcccagc cccctgagat tcgtaccctg gaaggatcct ctgccttctt gccctgctcc 120
ttcaatgcca gccaaaggag actggccatt ggctccgtca cgtgggtccg agatgaggtg 180
gttccaggga aggaggtgag gaatggaacc ccagagtcca ggggccgcct ggccccactt 240
gcttcttccc gtttcttcca tgaccaccag gctgagctgc acatccggga cgtgcgaggc 300
catgacgcca gcctctacgt gtgcagagtg gaggtgctgg gccttggtgt cgggacaggg 360
aatgggactc ggctggtggt ggagaaagaa catcctcagc taggggctgg tacagtccctc 420
ctccttcggg ctggattcta tgctgtcagc tttctctctg tggccgtggg cagcaccgtc 480
tattaccagg gcaaattgcca ctgtcacatg ggaacacact gccactcctc agatggggccc 540
cgaggrrgtg ttccagagcc cagatgtccc tag 573
```